Professor Mauro Perretti

Profile

ORCID iD: 0000-0003-2068-3331

Google Scholar

Degree in Medicinal Chemistry (1985) followed by a Master in Pharmacology and Toxicology (1988), both from the University of Florence, Italy. Doctorate from the University of London in 1996.

Academic path built on two fellowships from Arthritis Research Campaign (career development fellowship and senior fellowship): 1997-2007.

Senior roles: Deputy Director of William Harvey Research Institute (2006-2013); Co-Director of William Harvey Research Institute (2013-2016); Dean for Research and Research Impact of the Faculty of Medicine and Dentistry (2015-2022).

Research

Group members

Dr Magdalena KANEVA (senior post-doctoral fellow), Dr Chiara CECCONELLO (post-doctoral fellow), Dr Michele SUGIMOTO (post-doctoral fellow), Miss Marilena CHRISTOFOROU (PhD student), Mr Weifeng BU (PhD Student), Dr Hedayatullah HAYAT (QMUL/CARA Fellow), Miss Ayda Henriques SCHNEIDER (FAPESP Fellow).

Summary

Prof Perretti expertise are in the area of pathophysiology of inflammation with a strong attention to therapeutic opportunities. He has pioneered the studies on the biology of the Resolution of Inflammation, its mechanisms and mediators. Currently, Mauro and his team collaborate with commercial partners to establish resolution pharmacology, as a new branch where novel therapies could be developed on the science of resolution.

Publications

Full list of publications

1. Chen J, Austin-Williams S, O'Riordan CE, Claria-Ribas P, Sugimoto MA, Norling LV, Thiemermann C, Perretti M. Formyl peptide receptor type 2 (FPR2) deficiency in myeloid cells amplifies sepsis-induced cardiac dysfunction. J INNATE IMMUN. 2023 Apr 17. doi: 10.1159/000530284.
2. Qin CX, Norling LV, Vecchio EA, Brennan EP, May LT, Wootten D, Godson C, Perretti M*, Ritchie RH*. Formylpeptide receptor 2: Nomenclature, structure, signalling and translational perspectives: IUPHAR review 35. BR J PHARMACOL. 179(19):4617-4639, 2022.
3. Oggero S, Godec T, van Gorp R, Pinto AL, Schurgers LJ, Reutelingsperger C, Sever P, Norling LV, Perretti M*, Gupta A*.  Role of plasma extracellular vesicles in prediction of cardiovascular risk and alterations in response to statin therapy in hypertensive patients. J HYPERTENS. 40(8):1522-1529, 2022.
4. Oggero S, de Gaetano M, Marcone S, Fitzsimons S, Pinto AL, Ikramova D, Barry M, Burke D, Montero-Melendez T, Cooper D, Burgoyne T, Belton O, Norling LV, Brennan EP, Godson C, Perretti M. Extracellular vesicles from monocyte/platelet aggregates modulate human atherosclerotic plaque reactivity. J EXT VESICLES 10:12084, 2021.
5. Chen J, Norling LV, Mesa JG, Silva MP, Burton SE, Reutelingsperger C, Perretti M*, Cooper D*. Annexin A1 attenuates cardiac diastolic dysfunction in mice with inflammatory arthritis. PROC NATL ACAD SCI USA. 118(38):e2020385118, 2021.
6. Gadipudi LL, Ramavath NN, Provera A, Reutelingsperger C, Albano E, Perretti M*, Sutti S*. Annexin A1 treatment prevents the evolution to fibrosis of experimental nonalcoholic steatohepatitis. CLIN SCI (LOND). 136(9):643-656, 2022.

Collaborators

Internal

Dr Jianmin Chen; Dr Dianne Cooper; Dr Ajay Gupta; Dr Trini Montero-Melendez; Dr Suchita Nadkarni; Dr Lucy Norling; Dr Manikandan Subramanian; Prof Jesmond Dalli; Prof Magdi Yaqoob

External

Dr Stanly Fan (Barts Health NHS Trust); Prof Sandra Farsky (University of Sao Paulo, Brazil); Prof Catherine Godson (University College Dublin, Ireland); Dr Andreas Margraf (University of Münster, Germany); Dr Patricia Martins Silva (FioCruz, Rio de Janeiro, Brazil); Prof Chris Reutelingsperger (University of Maastricht, Netherlands); Prof Mauro M Teixeira (Federal University of Minas Gerais, Brazil).

News

• Resolution Pharmacology and AP1189 (SynAct Pharma), May 2023
• The Resolution of Inflammation / Neutrophil-derived microvesicles enter cartilage and protect the joint in inflammatory arthritis (Faculti), June 2017
• How Microvesicles could revolutionise arthritis treatment (The Conversation), November 2015
• Microvesicles are key to potential new study for treating arthritis (Arthritis Digest), November 2015
• New treatment could ease the agony of arthritis: Tiny bubbles made by the body's own cells may slash the need for surgery (Mail Online), November 2015
• Injection to end pain of arthritis: New treatment will stop agony without side effects (Daily Express), November 2015
• Neutrophil microvesicles protect cartilage in arthritis (Nature Reviews), December 2015
• New Class of Anti-Arthritis Drugs Effectively Treats Multiple Inflammatory Diseases (American Journal of Pathology), July 2014
• MRC Technology sells its Melanocortin Receptors Programme to Pfizer Inc, July 2014
• Inflammation: the Fire of Life (The Royal Society), June 2012

Teaching

• Lectures on receptor theory, inflammatory models and resolution of inflammation to undergraduate students (P&IT) and post-graduate students (BHF DTP).
• Assessor for student selected component years 2 and 4.

Disclosures

• Shareholder (ResoTher Pharma AS; Antibe Therapeutics)
• Scientific Advisory Board Member (SynAct Pharma, ResoTher Pharma)
• Director (William Harvey Research Limited)
• Consultancies (SynAct Pharma, BMS, Palatin Technologies)
• Collaborative Projects (TXP Pharma, BMS, BioAegis)